-
公开(公告)号：US10077431B2
公开(公告)日：2018-09-18
申请号：US15031763
申请日：2014-10-24
Applicant: PHERECYDES PHARMA
Inventor： Flavie Pouillot , Hélène Blois
IPC: A01N63/00 , A61K39/12 , A61K39/00 , A61K39/285 , A61K39/275 , C12N7/00 , A61K35/76 , C07K14/005 , C12Q1/18
CPC classification number: C12N7/00 , A61K35/76 , C07K14/005 , C12N2795/10121 , C12N2795/10122 , C12N2795/10132 , C12N2795/10171 , C12N2795/10221 , C12N2795/10222 , C12N2795/10232 , C12N2795/10271 , C12Q1/18
Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
-
公开(公告)号：US20170333498A1
公开(公告)日：2017-11-23
申请号：US15538538
申请日：2015-12-28
Applicant: Intron Biotechnology, Inc.
Inventor： Seong Jun Yoon , Sang Hyeon Kang , Soo Youn Jun , Hyoun Rok Paik , Jee Soo Son , Byung Kuk Kim , Hee Jeong Shin
CPC classification number: A61K35/76 , A23K10/18 , A23K20/10 , A23K20/195 , A23K50/30 , A23K50/60 , A61P31/04 , C12N7/00 , C12N2795/10121 , C12N2795/10132 , C12N2795/10171
Abstract: The present invention relates to a Myoviridae bacteriophage Esc-CHP-1 that is isolated from the nature and can kill specifically enterohemorrhagic E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12660BP), and a method for preventing and treating the infections of enterohemorrhagic E. coli using the composition comprising said bacteriophage as an active ingredient.
-
公开(公告)号：US20240342230A1
公开(公告)日：2024-10-17
申请号：US18427221
申请日：2024-01-30
Applicant: FERRING B.V. , INSTITUT PASTEUR
Inventor： Pascal Danglas , Laurent Debarbieux
CPC classification number: A61K35/76 , A61K9/0053 , C12N7/00 , C12N2795/10021 , C12N2795/10132 , C12N2795/10171 , Y02A50/30
Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease.
The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject.
The subject invention also provides new bacteriophage strains.
-
公开(公告)号：US20240209326A1
公开(公告)日：2024-06-27
申请号：US18598495
申请日：2024-03-07
Applicant: Eligo Bioscience
Inventor： Antoine Decrulle , Xavier Duportet , Igor STZEPOURGINSKI
IPC: C12N7/00 , A61K31/7088 , A61K38/46 , A61K39/00 , A61K39/108 , A61K45/06 , C12N9/22 , C12N15/11 , C12N15/70
CPC classification number: C12N7/00 , A61K31/7088 , A61K38/465 , A61K39/0258 , A61K45/06 , C12N9/22 , C12N15/11 , C12N15/70 , A61K2039/525 , A61K2039/53 , C12N2310/20 , C12N2795/10134 , C12N2795/10143 , C12N2795/10171 , C12N2795/10334 , C12N2795/10343 , C12N2795/10371 , C12N2800/80
Abstract: The present invention relates to the delivery of a payload by bacterial delivery vehicle, i.e. the encapsulation and the delivery of a single plasmid by different bacterial virus particles. More specifically, the present invention concerns a pharmaceutical composition comprising a payload packaged in at least two different bacterial delivery vehicles and a method of production thereof.
-
公开(公告)号：US11690885B2
公开(公告)日：2023-07-04
申请号：US16491176
申请日：2018-03-07
Applicant: PHERECYDES PHARMA
Inventor： Cindy Fevre , Hélène Blois , Mathieu Medina
CPC classification number: A61K35/76 , A01N63/40 , A61P31/04 , C07K14/005 , C12N7/00 , C12Q1/18 , A61K38/00 , C12N2795/10122 , C12N2795/10131 , C12N2795/10132 , C12N2795/10171 , C12N2795/10222 , C12N2795/10231 , C12N2795/10232 , C12N2795/10271
Abstract: The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Staphylococcus aureus strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy and as companion diagnostic.
-
6.发明授权
公开(公告)号：US09433653B2
公开(公告)日：2016-09-06
申请号：US14706325
申请日：2015-05-07
Applicant: iNtRON Biotechnology, Inc.
Inventor： Seong Jun Yoon , Soo Youn Jun , Hyoung Rok Paik , Jee Soo Son , Hye In Jeong , Sang Hyeon Kang
CPC classification number: A61K35/76 , C12N7/00 , C12N2795/00021 , C12N2795/00031 , C12N2795/00032 , C12N2795/10121 , C12N2795/10131 , C12N2795/10132 , C12N2795/10171 , Y02A50/473
Abstract: The present invention relates to a composition comprising the bacteriophage EK88P-1 isolated from the nature and having a broad antibacterial spectrum against E. coli as an active ingredient, and a method for preventing and treating E. coli infections using the said composition. The bacteriophage EK88P-1, the active ingredient of the composition of the present invention, has a broad antibacterial spectrum against E. coli and has the genome characteristically composed of the partial nucleotide sequences represented by SEQ ID NO: 1 to SEQ ID NO: 25, and also characterized by the bacteriophage belonging to the Myoviridae family according to the morphology that is composed of the major structural proteins in the sizes of approximately 49 kDa, 53 kDa, 94 kDa, and 103 kDa.
Abstract translation: 本发明涉及一种组合物，其包含从性质中分离的噬菌体EK88P-1，并具有对大肠杆菌作为活性成分的广谱抗菌谱，以及使用所述组合物预防和治疗大肠杆菌感染的方法。 噬菌体EK88P-1是本发明组合物的活性成分，对大肠杆菌具有广泛的抗菌谱，其特征在于由SEQ ID NO：1至SEQ ID NO：25表示的部分核苷酸序列组成的基因组 ，并且其特征还在于根据由约49kDa，53kDa，94kDa和103kDa的大小的主要结构蛋白质组成的形态的属于病毒科的噬菌体。
-
公开(公告)号：US12036255B2
公开(公告)日：2024-07-16
申请号：US18152077
申请日：2023-01-09
Applicant: Baylor College of Medicine , The United States of America as Represented by the Department of Veterans Affairs
Inventor： Anthony Maresso , Robert Ramig , Sabrina Green , Austen Terwilliger , Keiko Salazar , Justin R. Clark , Barbara Trautner
CPC classification number: A61K35/76 , A61P31/04 , C12N7/00 , C12N2795/10132 , C12N2795/10171 , C12N2795/10232 , C12N2795/10271
Abstract: Disclosed are compositions, devices, kits, and methods for treatment of Enterobacteriaceae infection. Aspects of the present disclosure are directed to bacteriophage compositions comprising one or more of ES17, ES19, HP3, HP3.1, and HP3.2. Certain aspects of the disclosure are directed to compositions comprising (a) bacteriophage ES17 or bacteriophage ES19, (b) bacteriophage HP3, and (c) bacteriophage HP3.1. Also disclosed are compositions comprising bacteriophage HP 3.2. Further disclosed are devices and kits comprising such compositions and methods for use of such compositions in treatment and prevention of pathogenic E. coli infection.
-
公开(公告)号：US20240226205A1
公开(公告)日：2024-07-11
申请号：US18592379
申请日：2024-02-29
Applicant: Armata Pharmaceuticals, Inc.
Inventor： Sébastien LEMIRE , Stacey Lynn KOLAR , Brian Clarke VARNUM
CPC classification number: A61K35/76 , A61K45/06 , A61P31/04 , C12N7/00 , C12N2795/10121 , C12N2795/10132 , C12N2795/10171 , C12N2795/10221 , C12N2795/10232 , C12N2795/10271
Abstract: The present disclosure relates to bacteriophages and compositions capable of infecting and killing Pseudomonas, and use of the same for treating Pseudomonas, e.g. Pseudomonas aeruginosa, bacterial infections.
-
公开(公告)号：US11952594B2
公开(公告)日：2024-04-09
申请号：US17406437
申请日：2021-08-19
Applicant: Eligo Bioscience
Inventor： Antoine Decrulle , Xavier Duportet , Igor Stzepourginski
IPC: C12N7/00 , A61K31/7088 , A61K38/46 , A61K39/108 , A61K45/06 , C12N9/22 , C12N15/11 , C12N15/70 , A61K39/00
CPC classification number: C12N7/00 , A61K31/7088 , A61K38/465 , A61K39/0258 , A61K45/06 , C12N9/22 , C12N15/11 , C12N15/70 , A61K2039/525 , A61K2039/53 , C12N2310/20 , C12N2795/10134 , C12N2795/10143 , C12N2795/10171 , C12N2795/10334 , C12N2795/10343 , C12N2795/10371 , C12N2800/80
Abstract: The present invention relates to the delivery of a payload by bacterial delivery vehicle, i.e. the encapsulation and the delivery of a single plasmid by different bacterial virus particles. More specifically, the present invention concerns a pharmaceutical composition comprising a payload packaged in at least two different bacterial delivery vehicles and a method of production thereof.
-
公开(公告)号：US20170281700A1
公开(公告)日：2017-10-05
申请号：US15623556
申请日：2017-06-15
Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. , HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
Inventor： Nissan Ronen HAZAN , Nurit BEYTH
CPC classification number: A61K35/76 , A61K9/0034 , A61K45/06 , C12N7/00 , C12N2795/10121 , C12N2795/10132 , C12N2795/10171
Abstract: Isolated bacteriophages having genomes comprising the nucleic acid sequences as set forth in SEQ ID NOs: 1 and 2, or variants thereof, and compositions comprising the bacteriophages in a ratio ranging from 1:10 to 10:1, respectively. Further provided are uses of the compositions in treating or preventing an infection inflicted by a bacteria (e.g., Enterococcous faecalis and/or Enterococcous faecium). As a non-limiting example, the composition may be used in treating or preventing a root canal infection.
